Purpose: BECTS (benign childhood epilepsy with centrotemporal spikes) is associated with characteristic EEG findings. This study examines the influence of anti-convulsive treatment on the EEG. Methods: In a randomized controlled trial including 43 children with BECTS, EEGs were performed prior to treatment with either Sulthiame or Levetiracetam as well as three times under treatment. Using the spike-wave-index, the degree of EEG pathology was quantified. The EEG before and after initiation of treatment was analyzed. Both treatment arms were compared and the EEG of the children that were to develop recurrent seizures was compared with those that were successfully treated. Results: Regardless of the treatment agent, the spike-wave-index was reduced significantly under treatment. There were no differences between the two treatment groups. In an additional analysis, the EEG characteristics of the children with recurrent seizures differed statistically significant from those that did not have any further seizures. Conclusion: Both Sulthiame and Levetiracetam influence the EEG of children with BECTS. Persistent EEG pathologies are associated with treatment failures.
Introduction
Benign childhood epilepsy with centrotemporal spikes (BECTS) is a common childhood disorder presenting with mostly sleeprelated seizures, mild neurocognitive impairment, and typical EEG changes [1] . There is currently no consent whether or not the condition should be treated, although it is proven that anticonvulsive treatment leads to a reduction of the seizure frequency [2] . There is no universal agreement on the choice of the treatment agent to treat BECTS. Levetiracetam and Sulthiame are among the established agents with a proven efficiency and moderate side effects [3] [4] [5] [6] .
The pathological interictal EEG-activity is known to be stable in the short term, but to vary in the course of months and years [7] . There are hints on a connection between interictal EEG activity and neurocognitive changes [8] [9] [10] . A marked decrease of interictal epileptiform activity has been shown for treatment with Sulthiame [11] and Clonazepam [12] and has been reported in the use of Oxcarbazepine [13] . There are contradictory studies regarding the influence of the administration of Levetiracetam on the EEG in BECTS and related conditions (e.g. ESES, "Electrical status epilepticus in sleep"). While some authors report an improvement of the EEG [14, 15] even at low doses [16] , there are as well opposing statements [6] . The effect of Levetiracetam on the nocturnal discharges in ESES could be shown in a placebo-controlled study [17] .
Here we present the results of a study comparing the effects of either Levetiracetam or Sulthiame on the EEG in BECTS.
Methods
The data were collected in the German HEAD study, a randomized, double-blind, controlled multicenter trial. It lasted from July 2006 to September 2008. A total of 44 patients were enrolled. The study design was in accordance with the declaration of Helsinki. The study was approved by the ethical review boards responsible for the 47 German centers joining the study.
Patients between the ages of 6 and 12 years with a diagnosis of BECTS (two or more seizures with typical semiology in a period of six months, presence of benign epileptic discharges in the EEG [18] ) and without prior treatment with anti-epileptic drugs were included. The exclusion criteria comprised relevant medical conditions, other types of epilepsies like CSWS (Continuous Spike-Wave during Slow Wave Sleep) and Landau-Kleffner, mental retardation, and the enrollment in other studies. For details see [19] .
The children were randomly assigned to two treatment arms, either Levetiracetam (LEV, final dosage: 30 mg/kg body weight per day, reduction to 20 mg/kg body weight in case of adverse effects) or Sulthiame (STM, daily 6 mg/kg body weight with the option of a reduction to 4 mg/kg). The randomization list was generated at the central randomization center of the manufacturer of the study medication using permuted blocks (block size 10, see [19] ). In both groups the dosage was increased on a weekly base, reaching maximum dosage after three weeks. EEGs were performed before treatment as well as about one week after reaching the final dosage (visit 2), after 12 weeks (visit 3) and at the end of the observation period (27 weeks, visit 4). The EEG recordings were planned to cover a total of 40 min per EEG.
EEG evaluation
All EEGs were evaluated by the same person (TB). The examiner was blinded with regard to all facts regarding the patients, including the assigned treatment arm. Sleep and awake periods were evaluated separately.
EEG evaluation included among other parameters:
The maximum sleep stage. The number of foci with interictal epileptiform discharges. For each focus: -The time fraction of epileptiform activity (spike-wave-index, SWI).
From these parameters, the "accumulated SWI" (AccSWI) was calculated. To calculate the raw SWI, the EEG is split into sections with a duration of one second each. The SWI for a given focus is defined as the percentage of periods with epileptiform discharges among all periods. Mathematically, it is the probability that a onesecond-period contains an epileptiform discharge. In the presence of multiple foci, the AccSWI is the probability that any focus produces a discharge within a period of one second. The AccSWI of two independent foci can therefore be calculated by:
AccSWIði; jÞ ¼ SWIðiÞ þ SWIðjÞ À ðSWIðiÞÁSWIðjÞÞ E.g. the combination of two foci with a SWI of 0.5 each leads to an AccSWI of 0.75. The accumulated SWI is the time fraction of epileptiform activity for the entire brain.
It is contrasted by the "maximum SWI" (MaxSWI) which is the maximum SWI over all foci in a given EEG.
Statistics
For statistic processing, the accumulated SWI was used. The results for two different parameters, the number of foci and the maximum SWI for all foci, can be found in a supplementary appendix. The analyses were performed for sleep and awake EEGs. Additionally, the maximum value of both vigilance levels was used for analysis.
Two different groupings were analyzed. The patients were sorted according to their treatment arm. The purpose of this subanalysis was to identify any differences between the treatment agents. Furthermore, the patients that had recurrent seizures were compared with those that were successfully treated. Here, the aim was to evaluate whether persistent interictal discharges can predict the recurrence of seizures.
The developments of the whole study population as well as the differences between the subgroups were compared using the Mann-Whitney U test. As a total of 67 different tests were performed (including the data presented in the supplementary appendix), the significance level had to be corrected to 0.00075 according to the Bonferroni-criterion.
Results
A total of 44 patients were enrolled. One of these patients had to be excluded due to a protocol violation. Due to treatment failures and adverse events, a total of 12 patients dropped out of the study, see Table 1 , from [19] .
The majority of the patients (36/41) were included in the year after the first seizure (14 of these in the first month). Four children were included in the second year after the manifestation of BECTS, the first seizure of one child was five years before inclusion. This child did still suffer from seizures (last seizure on the day prior to inclusion, total number of seizures: about 50).
The number of EEGs was lower than expected. For one patient, EEG data was not available at all. In some cases, the children were not able to sleep during the scheduled sleep EEGs. Other EEGs did not take place at all, or were not available for evaluation. See Table 2 for the total number of available EEGs.
In every visit after the initiation of treatment, more than half of the patients had normal EEGs. The majority of the EEG normalizations was sustained, i.e. there were no more discharges in any following visit. A non-negligible fraction did, however, have recurrent EEG pathologies after initial normalization. Table 3 shows the fraction of patients with a full EEG normalization. A "full normalization" was defined as the absence of EEG discharges in all available EEGs for a given patient at the specified visit. 
Accumulated SWI
The accumulated SWI was calculated for all EEG recordings. It showed a marked and statistically highly significant decrease after initiation of treatment in both treatment arms. There were no significant differences between the treatment arms. See Table 4 as well as Fig. 1 . Note that at visit 0, the two treatment groups were not well balanced.
The results of other measures than the accumulated SWI were similar and are presented in the supplementary appendix.
Correlation between EEG findings and recurrent seizures
The EEG characteristics regarding the drop-outs are depicted in Fig. 2 (accumulated SWI) . A visual interpretation of this data shows no hints on a correlation between the EEG changes and the occurrence of adverse effects. Therefore, the statistical evaluations were limited to a comparison between the patients with recurrent seizures and those that remained seizure-free. The results are presented in Table 5 .
Note that the results in the awake state at visit 3 are statistically significant. Table 6 shows the contingency table displaying the frequencies of a total (i.e. awake as well as asleep) EEG normalization and recurrent seizures. The P-value using Fisher's exact test is 0.0136, which is not statistically significant due to correction for multiple testing. Using these data, the sensitivity of persistent epileptiform discharges for recurrent seizures is 0.80, the specificity is 0.8125, the positive predictive value is 0.4 and the negative predictive value is 0.96.
There was no significant difference in the number of seizures before study initiation between the children that had recurrent seizures and those that were treated successfully (Mann-Whitney U test, P = 0.511).
Discussion
The data underlying this publication is based on a randomized controlled trial covering a total of 43 patients. The main weaknesses of the data set are the lack of an untreated control group as well as the failure to acquire sleep EEGs in all cases. The latter is important in the context of BECTS as an increase of the SWI in sleep is to be expected in this epilepsy syndrome [2] .
The analysis of the data in the HEAD study population showed a prompt, sustained and statistically significant response of the EEG on anti-convulsive treatment with either Levetiracetam or Sulthiame. There were no significant differences between the two agents used for treatment, Levetiracetam and Sulthiame. The results of this study do therefore not favor any anti-epileptic drug with regard to potential EEG effects.
The conclusion that anti-epileptic treatment with either Sulthiame or Levetiracetam has an influence in the interictal EEG is in line with prior studies [11, 13, 16, 14, 17] , but conflict with another evaluation comparing Levetiracetam and Oxcarbazepine [6] where both agents "had no influence . . . on the EEG paroxysmal focal discharges". The results section of this paper states only that there was no worsening of the EEG. EEG improvements are not mentioned throughout the publication. Therefore, we are not sure whether the phrase quoted above does indeed signify a lack of improvement in the EEG, or just that the EEG did not deteriorate.
The study included no placebo group to control for the natural history of the EEG in children with BECTS. Two studies providing data about the natural course of the EEG findings in BECTS could be identified [20, 7] . Both have similar inclusion criteria, and in both cases, all untreated children had an EEG at about six months. Pooling the results from these studies, 6/26 (23%) of the children showed a full EEG normalization six months after diagnosis. This differs significantly from the rate of 19/34 (56%) demonstrated in the study presented here at visit four (P = 0.0169, Fisher exact test). This suggests that the EEG response is attributable to treatment and not to the natural course of the disease. Results from a placebo- Table 3 Fraction of the normalized EEGs for all patients as well as for both subgroups. In brackets: Number of children that had a normal EEG in the respective visit that would have epileptiform activity in any of the following visits. E.g. 27(À8)/40: Forty children had an EEG, 27 of these EEGs were normal, eight of the children with normal EEGs at this visit had spikes in a later visit. Therefore, 19 children had a normal EEG in this and any following visit. controlled trial of Sulthiame in BECTS are consistent with this finding [11] . The data from the latter study was not included into the pooled placebo group as patients with treatment failures were excluded from the final analysis, therefore possibly introducing a bias. The EEGs of the children that eventually had recurrent seizures differed statistically significant from the EEGs of the successfully treated patients. This difference could be shown in the third study visit. A correction for multiple testing (using the Bonferroni method) was included into the statistical evaluations. It is justified to assume that the lack of statistically significant results in the other study visits might be attributable to a low sample size. Therefore, this study supports the use of the EEG to monitor the treatment of BECTS. The data support the hypothesis that a normalized EEG after 12 weeks of treatment can be seen as an indicator for a successful treatment.
We are not aware of any publications that showed an association between persistently pathological EEG findings and recurrent seizures in BECTS. The value of EEG as a monitoring tool is established in absence epilepsies [21] , but not in BECTS.
The symptoms of BECTS include both seizures and neuropsychological (cognitive as well as behavioral) dysfunctions. The latter might be the more relevant problems in a given child. The current study did not evaluate the correlation between the EEG findings and neuropsychological test results. This might be done in a future analysis.
Conclusion
The results from a randomized controlled multicenter trial show that treatment of patients with BECTS using either Levetiracetam or Sulthiame leads to a reduction of epileptiform discharges. Persistent epileptiform discharges after 12 weeks of treatment are associated with recurrent seizures. 
